NR3C2 and metabolic dysfunction-associated steatotic liver disease: As such, MR antagonists have emerged as promising therapeutic agents in the management of diseases characterized by chronic inflammation and tissue fibrosis, including MASLD and related cardiometabolic conditions [22,27,28].